Analysts See $0.30 EPS for Emergent BioSolutions Inc. (EBS); Weyerhaeuser Company (WY) Covered By 8 Bulls

April 25, 2018 - By Darrin Black

Weyerhaeuser Company (NYSE:WY) Logo

Among 14 analysts covering Weyerhaeuser Company (NYSE:WY), 8 have Buy rating, 1 Sell and 5 Hold. Therefore 57% are positive. Weyerhaeuser Company had 35 analyst reports since September 11, 2015 according to SRatingsIntel. The rating was downgraded by BMO Capital Markets on Monday, August 14 to “Market Perform”. The rating was downgraded by Bank of America to “Neutral” on Wednesday, July 5. The rating was downgraded by DA Davidson to “Neutral” on Monday, May 9. The company was downgraded on Tuesday, May 3 by Vertical Research. The company was downgraded on Thursday, December 15 by CLSA. The rating was maintained by BMO Capital Markets with “Buy” on Wednesday, July 26. The stock of Weyerhaeuser Company (NYSE:WY) earned “Buy” rating by Dundee Securities on Tuesday, January 19. BMO Capital Markets maintained the stock with “Buy” rating in Thursday, June 22 report. The firm has “Buy” rating given on Wednesday, April 19 by RBC Capital Markets. The company was maintained on Monday, September 4 by RBC Capital Markets. See Weyerhaeuser Company (NYSE:WY) latest ratings:




24/01/2018 Broker: Bank of America Old Rating: Neutral New Rating: Buy Upgrade
08/11/2017 Broker: RBC Capital Markets Rating: Buy New Target: $40.0 Maintain
02/11/2017 Broker: Argus Research Rating: Buy Old Target: $37 New Target: $39 Maintain
29/10/2017 Broker: BMO Capital Markets Rating: Hold New Target: $36.0 Maintain

Analysts expect Emergent BioSolutions Inc. (NYSE:EBS) to report $0.30 EPS on May, 3.They anticipate $0.01 EPS change or 3.45% from last quarter’s $0.29 EPS. EBS’s profit would be $14.94M giving it 43.08 P/E if the $0.30 EPS is correct. After having $0.74 EPS previously, Emergent BioSolutions Inc.’s analysts see -59.46% EPS growth. The stock decreased 5.18% or $2.82 during the last trading session, reaching $51.7. About 24,460 shares traded. Emergent BioSolutions Inc. (NYSE:EBS) has risen 82.65% since April 25, 2017 and is uptrending. It has outperformed by 71.10% the S&P500.

Investors sentiment increased to 2.02 in 2017 Q4. Its up 0.33, from 1.69 in 2017Q3. It increased, as 11 investors sold Emergent BioSolutions Inc. shares while 53 reduced holdings. 45 funds opened positions while 84 raised stakes. 36.89 million shares or 8.80% more from 33.90 million shares in 2017Q3 were reported. Piedmont Inv Advsrs Limited Liability Co stated it has 7,334 shares. Virginia Retirement Et Al accumulated 52,200 shares. Principal Fincl Gru Inc accumulated 284,708 shares or 0.01% of the stock. Great West Life Assurance Can accumulated 46,280 shares. First Quadrant Lp Ca invested in 0.01% or 12,308 shares. Shell Asset Management reported 14,608 shares. Strs Ohio stated it has 117,700 shares. Glenmede Company Na invested 0.19% in Emergent BioSolutions Inc. (NYSE:EBS). Zacks Invest Mgmt holds 0.02% of its portfolio in Emergent BioSolutions Inc. (NYSE:EBS) for 18,945 shares. Hbk Invests Limited Partnership accumulated 12,300 shares. 16,981 are held by Amer Century Cos Inc. The Massachusetts-based Numeric Invsts Limited Liability Company has invested 0.04% in Emergent BioSolutions Inc. (NYSE:EBS). Citadel Advsr Ltd accumulated 10,726 shares or 0% of the stock. Acadian Asset Mngmt Ltd Liability Corp accumulated 1.45M shares or 0.29% of the stock. State Street Corp owns 0.01% invested in Emergent BioSolutions Inc. (NYSE:EBS) for 1.50M shares.

Emergent BioSolutions Inc. focuses on the development, manufacture, and commercialization of medical countermeasures that address public health threats. The company has market cap of $2.58 billion. The Company’s products address public health threats primarily chemical, biological, radiological, nuclear, and explosive-related threats, as well as infectious diseases. It has a 30.3 P/E ratio. The company's marketed products include BioThrax, an anthrax vaccine; Anthrasil, a polyclonal antibody for the treatment of inhalational anthrax; BAT for the treatment of botulinum disease; vaccinia immune globulin intravenous that addresses adverse events from smallpox vaccination; reactive skin decontamination lotion kit for the removal or neutralization of chemical warfare agents; and Trobigard, an auto-injector device designed for intramuscular self-injection of atropine sulfate and obidoxime chloride.

Since December 12, 2017, it had 0 insider purchases, and 7 sales for $4.26 million activity. Havey Adam sold $93,951 worth of stock. 21,906 shares valued at $1.05 million were sold by Abdun-Nabi Daniel on Tuesday, January 2. 7,729 shares were sold by Hauer Jerome M, worth $391,787. 7,893 shares were sold by Richard Ronald, worth $434,115 on Tuesday, April 17.

Among 5 analysts covering Emergent Biosolutions (NYSE:EBS), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. Emergent Biosolutions had 9 analyst reports since August 10, 2015 according to SRatingsIntel. The company was maintained on Tuesday, June 28 by Singular Research. The stock of Emergent BioSolutions Inc. (NYSE:EBS) has “Buy” rating given on Tuesday, February 27 by Singular Research. Cowen & Co maintained the stock with “Hold” rating in Friday, July 14 report. The company was initiated on Friday, April 15 by Chardan Capital Markets. The firm earned “Outperform” rating on Friday, February 19 by Wells Fargo. Singular Research initiated it with “Buy” rating and $44 target in Monday, March 28 report. On Monday, August 10 the stock rating was upgraded by Zacks to “Hold”.

Investors sentiment increased to 1.14 in 2017 Q4. Its up 0.04, from 1.1 in 2017Q3. It increased, as 34 investors sold Weyerhaeuser Company shares while 268 reduced holdings. 71 funds opened positions while 272 raised stakes. 545.30 million shares or 1.12% less from 551.50 million shares in 2017Q3 were reported. Stevens Cap Lp invested in 0.49% or 359,308 shares. Fiduciary Financial Services Of The Southwest Tx has 0.1% invested in Weyerhaeuser Company (NYSE:WY) for 9,340 shares. Key Holdg (Cayman) Limited has invested 0.1% in Weyerhaeuser Company (NYSE:WY). Asset One Limited has 0.09% invested in Weyerhaeuser Company (NYSE:WY) for 1.19 million shares. Johnson Inv Counsel accumulated 24,721 shares. Zeke Advsrs Limited Liability reported 31,079 shares or 0.11% of all its holdings. Stevens First Principles Invest Advsrs reported 245,948 shares stake. Catawba Cap Management Va reported 137,921 shares stake. Voloridge Limited Liability Com stated it has 66,675 shares or 0.05% of all its holdings. Patten Patten Tn holds 1.98% or 561,363 shares. 24,666 are owned by Cibc Markets Incorporated. Prentiss Smith Com accumulated 808 shares. Franklin Res holds 0% of its portfolio in Weyerhaeuser Company (NYSE:WY) for 230,081 shares. Thrivent Fincl For Lutherans accumulated 614,381 shares. 3,998 are owned by Amica Retiree Medical.

Weyerhaeuser Company (NYSE:WY) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts